Korean Tagrisso Launch Builds On Extensive Local Data
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca's Tagrisso has debuted in South Korea, raising hopes and treatment options for certain types of lung cancer patients, but the product will face immediate local direct competition from Hanmi’s recently launched rival olmutinib.
You may also be interested in...
Tagrisso Reimbursed In Korea, After Difficult Price Negotiations
Korea's National Health Insurance Service and AstraZeneca reach an agreement on reimbursement of Tagrisso, sharply reducing financial burdens of NSCLC patients in the country. Tough price negotiations between the two sides underlines the difficulties pricey innovative drugs face to get reimbursed in the country.
AstraZeneca’s Emerging Markets Growth Not All About China
In contrast to some of its multinational peers, AstraZeneca is steaming full ahead in its main emerging markets, logging strong growth on the back of its respiratory franchise and newer products.
Yuhan, Luoxin Deal Underscores Asian NSCLC Therapy Needs
Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.